Mission Statement, Vision, & Core Values (2026) of Novogene Co., Ltd.

Novogene Co., Ltd. (stock code 688315.SS) has, since its founding in March 2011, grown into a global multi-omics powerhouse with state-of-the-art laboratories across 6 countries-the United States, the United Kingdom, Germany, China, Singapore, and Japan-delivering Next-Generation Sequencing (NGS), proteomics and metabolomics at scale through high-throughput sequencing and high-performance computing platforms that process large-scale genomic data for researchers, hospitals, pharmaceutical firms and agricultural enterprises; guided by the compact mission "Advancing Genomics, Improving Life," Novogene pursues sustainable, compliant corporate governance while its team- the majority holding advanced degrees from top institutions-drives innovation, professionalism, integrity and partnership to provide fast, reliable, cost-effective, automated and digitized genomic services and solutions worldwide, underscored by numerous academic and industry collaborations that continually expand its technical and service footprint.

Novogene Co., Ltd. (688315.SS) - Intro

• Core service areas: high-throughput NGS, clinical genomics, single-cell sequencing, proteomics, metabolomics, and bioinformatics/AI-driven analysis.
• Global operations: laboratories and R&D centers across the United States, the United Kingdom, Germany, China, Singapore, and Japan.
• Customer base: academic institutions, hospitals, pharmaceutical and biotech companies, agricultural enterprises, and government research agencies.

• Mission: Deliver accurate, fast, and affordable multi-omics services and analytical solutions to empower scientific discovery and improve human and environmental health worldwide.
• Vision: Be the trusted global partner for comprehensive genomic and multi-omics solutions that translate complex biological data into actionable insights for medicine, agriculture, and industry.
• Core values:
  • Scientific excellence - rigorous methods, continual validation, and adoption of cutting-edge sequencing and proteomics technologies.
  • Customer-centricity - tailored workflows, fast turnaround, and data security to meet diverse research and clinical needs.
  • Innovation - sustained investment in R&D, automation, and bioinformatics to scale multi-omics capabilities.
  • Integrity & compliance - adherence to regulatory, ethical, and quality standards in all markets served.
  • Collaboration - partnerships with academia, hospitals, and industry to co-develop solutions and translate discoveries.

• High-throughput sequencing: scalable NGS pipelines for whole-genome, exome, transcriptome, methylation, and targeted panels with rapid turnaround.
• Proteomics & metabolomics: quantitative mass-spectrometry workflows integrated with bioinformatics for biomarker discovery and pathway analysis.
• Clinical genomics: CLIA/CAP-style quality systems in applicable markets, variant interpretation, and clinical reporting pipelines.
• Bioinformatics & HPC: dedicated high-performance computing clusters and proprietary pipelines to store, process, and analyze large-scale genomic datasets.
• Custom solutions: assay development, contract research, and partnership programs for co-development with industrial and academic collaborators.

• Scalability: Investment in automation and sequencing capacity supports economies of scale, lowering per-sample cost and enabling large consortia projects.
• Diversification: Multi-omics services and clinical offerings broaden revenue streams across research, clinical, pharmaceutical, and agricultural markets.
• Partnerships: Collaborative agreements with leading universities, hospitals, and biotech firms amplify innovation and commercial pipelines.
• Data-driven value: Proprietary bioinformatics and AI-enabled analytics convert raw multi-omics data into actionable insights for clients, underpinning higher-value service tiers.

• Academic & hospital partnerships: joint research programs and large-cohort sequencing initiatives providing disease genomics and population genetics insights.
• Pharma & biotech: support for drug discovery, target validation, biomarker discovery, and clinical trial sequencing needs.
• Agriculture: genomic selection and breeding programs leveraging sequencing to improve crop and livestock traits.

Novogene Co., Ltd. (688315.SS) - Overview

• Core mission: advance genetic technologies and provide sequencing, bioinformatics and related solutions to accelerate scientific discovery and applied outcomes across sectors.
• Scope of impact: human health (clinical genomics and precision medicine), agricultural genomics (crop and livestock improvement), microbial and environmental genomics.
• Governance aims: build a listed company with clear systems, defined responsibilities, robust compliance, and efficient coordinated operation.
• Sustainability focus: integrate high-quality development and environmental/social governance into day-to-day operations and long-term strategy.

• Strategic initiatives: expand global sequencing capacity, scale clinical services, deepen partnerships with research institutions and biopharma, and commercialize applied genomics solutions.
• Operational priorities: quality and turnaround-time improvements, platform standardization, and reproducible bioinformatics pipelines governed by compliance frameworks.

• Core values driving execution:
  • Scientific excellence - rigorous methods, reproducibility and continuous innovation.
  • Integrity & compliance - regulatory adherence, ethical sample and data handling.
  • Customer-centricity - tailored solutions, quality assurance and timely delivery.
  • Collaboration - partnerships across academia, industry and healthcare systems.
  • Sustainability - embedding ESG considerations into business processes.

Novogene Co., Ltd. (688315.SS) - Mission Statement

• Provide first-class genomic sequencing, bioinformatics, and laboratory services globally with rapid turnaround and reproducible, high-quality results.
• Drive automation and digitization across laboratory workflows and informatics pipelines to reduce costs, increase throughput, and improve result consistency.
• Continuously refine incumbent services while incubating novel solutions (e.g., single-cell, long-read, clinical-grade assays) to expand the product and services portfolio.
• Operate with a customer-first mindset-prioritizing responsiveness, transparency, and tailored solutions to enhance user experience and long-term partnerships.

• Quality & reproducibility: Standardized SOPs, QC metrics, and validated pipelines ensure consistent output across global sites.
• Automation & digitization: Investments in robotics, LIMS, and cloud-native bioinformatics reduce manual error and shorten lead times.
• Customer responsiveness: Tiered service offerings and account management reduce ramp-up time for large-scale projects and bespoke initiatives.
• Cost-efficiency at scale: Centralized procurement, high instrument utilization, and optimized workflows enable competitive pricing for high-throughput customers.

• Novogene envisions being the global leader in genomic services and solutions-pursuing international recognition and technology leadership through scalable operations and continuous innovation.
• The mission's emphasis on automation, digitization, and customer-first delivery directly supports that vision by making high-quality genomics accessible, timely, and cost-effective worldwide.
• Consistency over time: The company's strategic investments and service roadmaps reflect a sustained commitment to excellence, customer satisfaction, and expansion of global capabilities.

Novogene Co., Ltd. (688315.SS) Vision Statement

• Global leadership in genomic services and solutions, expanding service capacity while maintaining rigorous quality and turnaround times.
• Continual investment in technology platforms to reduce per-sample cost and increase throughput, enabling broader access to genomics.
• Long-term partnerships with academic institutions, biotech, pharmaceutical and agricultural companies to translate genomic insights into measurable outcomes.

• Professionalism - delivering scientific expertise, accurate data and practical application guidance to customers worldwide.
• Innovation - driving continuous technology development, analytical methods and business-model improvements to stay at the cutting edge.
• Integrity - committing to transparency, ethical data handling and honest stakeholder communication.
• Partnership - creating win-win relationships by fully evaluating partners' interests and focusing on mutual long-term benefits.

• Professionalism: dedicated scientific teams provide application consulting, protocol optimization and interpretation services; customer satisfaction and sample success rates are key KPIs.
• Innovation: sustained R&D programs and platform upgrades target throughput, accuracy and cost-per-base reductions; intellectual property is retained to secure competitive advantage.
• Integrity: standardized SOPs, ISO/CLIA-like quality frameworks and transparent reporting ensure reliability and regulatory compliance.
• Partnership: focused account teams and joint-development agreements align incentives for long-term collaborations.

• Professionalism: measurable service SLAs (turnaround times, Q30/Q20 metrics), technical training programs and customer-facing scientific advisory units.
• Innovation: allocating a significant portion of revenue to R&D; pilot programs for automation, AI-driven variant interpretation and cost reduction initiatives.
• Integrity: compliance frameworks, independent audits and public reporting to maintain stakeholder trust and regulatory alignment.
• Partnership: structured co-development, revenue-sharing and long-term supply agreements with pharma, CROs and agricultural genetics partners.

• Cross-functional teams and matrix management reduce silos and accelerate project delivery.
• Performance metrics emphasize team outcomes and company-wide interests for sustainable strategic development.
• Knowledge-sharing platforms and internal training keep scientific staff aligned with evolving technologies and customer needs.